Recruiting closed - Study ongoing
Once enough participants have been enrolled in a study, it will be closed to further recruitment. The people already taking part in the study will continue to have their scheduled study visits until they complete the study.
The studies are arranged alphabetically on this page.
COVID-19 - Vaccine study in children (COV006)
Title: A phase II study of a candidate COVID-19 vaccine in children.
The purpose of this study is to test a new vaccine against COVID-19 in children and young adults aged 6-17 years.
This study will enable us to assess if children can be protected from COVID-19 with this new vaccine called ChAdOx1 nCoV-19. It will also give us valuable information on safety aspects of the vaccine and its ability to generate good immune responses against the virus, in children and young people. We will do this by randomly allocating participants to receive the COVID-19 vaccine or a control injection in addition to doing blood tests and collecting information about any symptoms that occur after vaccination.
If you have a query about the study, please refer to the COV006 Information Sheet (PDF, 1,144kB) before contacting the study team.
Com-COV3
Title: Comparing COVID-19 Vaccine Schedule Combinations in adolescents (Com-COV3)
This study aims to compare two different COVID-19 vaccines at different doses as a boost in young people aged 12-16 years who have received either 0 or 1 dose of the Pfizer vaccine.
For more details, please visit the ComCov study website.
Longitudinal Study of COVID-19: Symptoms, Virology & Immunity Study (LOGIC)
Title: Longitudinal Study of COVID-19: Symptoms, Virology & Immunity Study
The LOGIC Study is a longitudinal cohort study aiming to answer basic questions about COVID-19, which would help to achieve and redefine current strategies to overcome the virus. We are particularly interested in studying symptoms, virology and immunity in detail over three months in frontline healthcare workers at the Children’s Emergency Department (CED) of Bristol Royal Hospital for Children.
If you have a query about the study, please refer to the LOGIC Patient Information Sheet before contacting the study team.
SPIT - Study to evaluate prevalence of meningococcal carriage in teenagers
Title: Feasibility of, and methodological approaches to, a teenage evaluation of MenB vaccination and meningococcal carriage
Teenagers are at increased risk of meningococcal disease. Although this rare disease can be serious, the meningococcus germ is “carried” in the back of the throat without causing any symptoms in about one in five teenagers.
We want to understand how “carriage” of this germ varies over time, and whether immunisation with the new “meningococcus B” vaccine (Bexsero) is likely to change this.
To do this, we need to collect samples from healthy people before and after they have received the new meningococcus B vaccine (Bexsero). This research will help us to understand how vaccines can protect people against this disease.
If you have a query about the study, please refer to the SPIT Information Sheet (PDF, 181kB) before contacting the study team.
TOP - Transmission of Pneumococcus
Title: Evaluation of the relationship between pneumococcal colonisation density in 2-year-old children and rates of transmission to family contacts using live attenuated intranasal influenza vaccine as a probe. A randomised prospective step-wedge multicentre study.
Pneumococcus is a common bacterium that usually lives in the noses of young children without causing any illness. Occasionally, it causes diseases like ear infections and pneumonia (chest infection) and very rarely meningitis.
The nasal spray flu vaccine (FluenzTetra) used in this study, is offered to all 2-10-year-old children in the UK. It contains weakened live flu viruses that do not cause illness and protect them against the flu. This vaccine can also increase the number of pneumococcus bacteria in the noses of children who are carrying the bacteria without making them sick.
The nasal flu vaccine is the licensed vaccine that all two to ten-year-old children are routinely offered in the UK every autumn which is known to be safe and effective. The vaccine causes a very mild flu infection and so protects against real flu but the mild infection can change the numbers of other bugs in the nose too without causing any illness. We are conducting this study to find out whether those changes result in those bugs being passed around within the family differently. Nothing in the study changes anything that would be happening anyway, it just tracks what is going on. By understanding how these bugs are spread, we will be able to plan more effective strategies to prevent infections in the future.
If you have a query about the study, please refer to the TOP Information Sheet before contacting the study team.
Valneva Adolescent COVID study
Title: COV-COMPARE Immunogenicity of vaccine VLA2001 compared to AZD1222.
Valneva is now starting a Phase 3 clinical trial in adolescents aged 12-17 years to test a new candidate vaccine against COVID-19. The vaccine company Valneva is starting a Phase 3 clinical trial in adolescents aged 12-17 years to test a new candidate vaccine against COVID-19 compared to a placebo. Participation involves up to 8 visits over the course of 12 months. Study participants will be compensated for their time and participation.
If you have a query about the study, please refer to the Valneva COVID-19 Information Sheet (PDF, 333kB), or you can a call Bristol Vaccine Centre on 117 342 0170 or email valneva-study@bristol.ac.uk with any questions.
To sign up and find out more information, Valneva study website.
HARMONIE Study
Title: Study to Prevent Respiratory Infection in Infants including bronchiolitis, pneumonia and other chest infections often cause by the Respiratory Syncytial Virus
The HARMONIE Research Study is looking at how strongly babies can be protected from serious illness due to RSV infection (respiratory syncytial virus) by giving them a single antibody dose.
RSV is a common seasonal virus that infects nearly all babies by their second birthday. Most of the time it causes a mild illness, like a cold. However, for some babies, it leads to more severe lung problems such as bronchiolitis and pneumonia.
The HARMONIE Study will include as many as 28,860 babies, from newborns to babies 12 months old, in the UK, France, and Germany.
If the study is appropriate for your baby, they will be randomly assigned into one of two groups. One group will receive the antibody dose by having an injection into their thigh, in the same way your baby will receive their routine vaccination injections, and the other group no injection will be given.
For more information, please read the harmony parent information sheet (PDF, 393kB)
You can a call Bristol Vaccine Centre on 0117 342 0160 or email harmonie-study@bristol.ac.uk with any questions
SUPER Study
Title: Evaluating a new vaccine for the prevention of whooping cough
This study will measure the effects if a new nasal vaccine against pertussis (whooping cough) and compare them to those of an already approved vaccine.
Children/teenagers (6-16 years old) who take part will receive a dose of the study vaccine or placebo (a spray up the nose) and/or a dose of an approved vaccine or placebo against pertussis (an injection in the arm).
Pertussis is a highly contagious disease which is transmitted via one`s airways by a bacteria called Bordetella pertussis. If left untreated, the bacteria can cause extreme repeated coughing spells that can last for months, when spread to small infants it can be potentially life-threatening. Outbreaks in school age children (ages 6-17) have significantly increase in the United Kingdom with epidemics reported every 3-5 years. These outbreaks are occurring even though children and teens received current pertussis vaccines during early childhood.
For more information, please visit the study website SUPER TRIAL | Be a SUPER hero Standing Up to PERtussis or read the Super Study parent information sheet (PDF, 526kB).
You can a call Bristol Vaccine Centre on 0117 342 0160 or email nasal-pertussis@bristol.ac.uk with any questions.
STOP RSV
Title: Surveillance towards Preventing RSV Respiratory Infection in Children.
Chest infections such as bronchiolitis can occur when a common cough or cold virus moves from the nose to the lungs leading to difficulty breathing. Often this is caused by the Respiratory Syncytial Virus (RSV). Young children have smaller airways and less immunity so are at more risk. Each year as many as 4 in 100 children under 3 are admitted to hospital.
The aim of the study is to find out more about respiratory infections caused by this virus and what impact this illness has for children, families, and health care.
Please note children are recruited for this study when attending hospital with respiratory symptoms, for more information please see the Stop RSV Patient Information Sheet (PDF, 187kB).
You can a call Bristol Vaccine Centre on 0117 342 0160 or email stop-rsv@bristol.ac.uk with any questions.